Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1068-1071

  Fabiani, Emiliano ^a   D'Alò, Francesco ^a   Scardocci, Alessandra ^a   Greco, Mariangela ^a   Di Ruscio, Annalisa ^a   Criscuolo, Marianna ^a   Fianchi, Luana ^a   Pagano, Livio ^a   Hohaus, Stefan ^a   Leone, Giuseppe ^a   Voso, Maria Teresa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Detoxification; DNA repair; Myelodysplastic Syndromes; Polymorphisms; Prognosis

Indexed keywords

CYTOCHROME P450 3A4; DNA; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; OXIDOREDUCTASE; RAD51 PROTEIN; XENOBIOTIC AGENT; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC3 PROTEIN;

AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; DNA REPAIR; FEMALE; GENE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK ASSESSMENT;

AGED; ALLELES; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA REPAIR; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, GENETIC; RISK FACTORS; SURVIVAL RATE; XENOBIOTICS;

EID: 67349137713     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.10.012     Document Type: Article

References (30)

1. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
2. Leone G., Pagano L., Ben-Yehuda D., and Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92 (2007) 1389-1398
3. Chen H., Sandler D.P., Taylor J.A., Shore D.L., Liu E., Bloomfield C.D., et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347 (1996) 295-297
4. Sasai Y., Horiike S., Misawa S., Kaneko H., Kobayashi M., Fujii H., et al. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res 23 (1999) 975-981
5. Tsabouri S.E., Georgiou I., Alamanos I., and Bourantas K.L. Increased prevalence of GSTM(1) null genotype in patients with myelodysplastic syndrome: a case-control study. Acta Haematol 104 (2000) 169-173
6. Sutton J.F., Stacey M., Kearns W.G., Rieg T.S., Young N.S., and Liu J.M. Increased risk for a plastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr Blood Cancer 42 (2004) 122-126
7. Kim H.N., Kim Y.K., Lee I.K., Yang D.H., Lee J.J., Shin M.H., et al. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res, Leuk Res. (2008) [Epub ahead of print]
8. Broberg K., Höglund M., Gustafsson C., Björk J., Ingvar C., Albin M., et al. Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma. Cancer Lett 258 (2007) 38-44
9. Naoe T., Takeyama K., Yokozawa T., Kiyoi H., Seto M., Uike N., et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6 (2000) 4091-4095
10. Bolufer P., Collado M., Barragan E., Calasanz M.J., Colomer D., Tormo M., et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 136 (2007) 590-596
11. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 98 (2001) 11592-11597
12. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
13. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
14. Seedhouse C., Faulkner R., Ashraf N., Das-Gupta E., and Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 10 (2004) 2675-2680
15. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75 (1997) 69-75
16. Coles B.F., Morel F., Rauch C., Huber W.W., Yang M., Teitel C.H., et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11 (2001) 663-669
17. Hohaus S., Di Ruscio A., Di Febo A., Massini G., D'Alo' F., Guidi F., et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 11 (2005) 2175-2179
18. Allan J.M., Smith A.G., Wheatley K., Hills R.K., Travis L.B., Hill D.A., et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104 (2004) 3872-3877
19. Voso M.T., D'Alo' F., Putzulu R., Mele L., Scardocci A., Chiusolo P., et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 100 (2002) 2703-2707
20. Voso M.T., Fabiani E., D'Alo' F., Guidi F., Di Ruscio A., Sica S., et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 18 (2007) 1523-1528
21. Zimniak P., Nanduri B., Pikuła S., Bandorowicz-Pikuła J., Singhal S.S., Srivastava S.K., et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 224 (1994) 893-899
22. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., et al. Regulation of JNK signaling by GSTp. EMBO J 18 (1999) 1321-1334
23. Gate L., Majumdar R.S., Lunk A., and Tew K.D. Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways. J Biol Chem 279 (2004) 8608-8616
24. Ruscoe J.E., Rosario L.A., Wang T., Gaté L., Arifoglu P., Wolf C.R., et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 298 (2001) 339-345
25. Arruda V.R., Lima C.S., Grignoli C.R., de Melo M.B., Lorand-Metze I., Alberto F.L., et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol 66 (2001) 383-388
26. D'Alò F., Voso M.T., Guidi F., Massini G., Scardocci A., Sica S., et al. Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica 89 (2004) 664-670
27. Barragan E., Collado M., Cervera J., Martin G., Bolufer P., Roman J., et al. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 31 (2007) 947-953
28. Bhatla D., Gerbing R.B., Alonzo T.A., Mehta P.A., Deal K., Elliott J., et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia 22 (2008) 265-272
29. Voso M.T., Hohaus S., Guidi F., Fabiani E., D'Alò F., Groner S., et al. Prognostic role of glutathione S-transferase (GST) polymorphisms in acute myeloid leukemia. Leukemia 22 (2008) 1685-1691
30. Raza A., Melcert M., Galili N., Smith S.E., Godwin J.E., Young S., et al. Phase 1 dose escalation study of TLK199 tablets (Telintra), a novel glutathione analog, in myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 110 (2007) 1454